Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

94.80EUR
11:36am BST
Change (% chg)

€1.02 (+1.09%)
Prev Close
€93.78
Open
€93.50
Day's High
€95.02
Day's Low
€93.50
Volume
134,842
Avg. Vol
550,966
52-wk High
€102.90
52-wk Low
€79.26

Latest Key Developments (Source: Significant Developments)

Merck KGaA CFO Says No Concrete Plans At The Moment To Divest Any Businesses
Friday, 12 Apr 2019 

April 12 (Reuters) - Merck Kgaa analyst call::CFO SAYS NO SIZABLE TAKEOVER TRANSACTIONS PLANNED IN THE FORESEEABLE FUTURE AFTER VERSUM DEAL, DELEVERAGING IS FOCUS OVER NEXT COUPLE OF YEARS.CFO SAYS WANT TO KEEP A DIVERSIFIED 3 PILLAR STRUCTURE FOR THE COMPANY.CFO SAYS THERE ARE NO CONCRETE PLANS AT THE MOMENT TO DIVEST ANY BUSINESSES IN THE NEAR FUTURE.  Full Article

FDA Approves New Oral Treatment For Multiple Sclerosis
Friday, 29 Mar 2019 

March 29 (Reuters) - Merck KGaA ::FDA APPROVES NEW ORAL TREATMENT FOR MULTIPLE SCLEROSIS.FDA - APPROVED MAVENCLAD TABLETS TO TREAT RELAPSING FORMS OF MS IN ADULTS, TO INCLUDE RELAPSING-REMITTING DISEASE & ACTIVE SECONDARY PROGRESSIVE DISEASE.FDA - GRANTED APPROVAL OF MAVENCLAD TO EMD SERONO INC.FDA - MAVENCLAD HAS A BOXED WARNING FOR AN INCREASED RISK OF MALIGNANCY AND FETAL HARM.FDA - MAVENCLAD IS NOT RECOMMENDED FOR MS PATIENTS WITH CLINICALLY ISOLATED SYNDROME.  Full Article

Entegris Says Believes Combination Of Entegris & Versum To Be In Best Interests Of Stockholders Of Each Co
Friday, 29 Mar 2019 

March 29 (Reuters) - Entegris Inc ::ENTEGRIS COMMENTS ON VERSUM MATERIALS ANNOUNCEMENT.ENTEGRIS INC - BELIEVES COMBINATION OF ENTEGRIS AND VERSUM TO BE IN BEST INTERESTS OF STOCKHOLDERS OF EACH COMPANY.ENTEGRIS INC - BOARDS OF ENTEGRIS AND VERSUM MATERIALS CONTINUE TO RECOMMEND PREVIOUSLY ANNOUNCED MERGER.  Full Article

Versum Materials' Board Of Directors Rejects Unsolicited Tender Offer From Merck KGaA
Friday, 29 Mar 2019 

March 29 (Reuters) - Versum Materials Inc ::VERSUM MATERIALS’ BOARD OF DIRECTORS REJECTS UNSOLICITED TENDER OFFER FROM MERCK KGAA.VERSUM MATERIALS INC - DETERMINES TO ENGAGE IN DISCUSSIONS WITH MERCK.VERSUM MATERIALS INC - MEETING OCCURRED BETWEEN REPRESENTATIVES OF VERSUM AND MERCK PURSUANT TO A LIMITED WAIVER GRANTED BY ENTEGRIS.VERSUM MATERIALS- AFTER CONSIDERATION, CONSULTATION WITH FINANCIAL, LEGAL ADVISORS, BOARD DETERMINED TO REJECT UNSOLICITED TENDER OFFER FROM MERCK KGAA.VERSUM MATERIALS - DETERMINED MERCK'S PROPOSAL COULD REASONABLY BE EXPECTED TO RESULT IN SUPERIOR PROPOSAL UNDER MERGER AGREEMENT WITH ENTEGRIS.VERSUM MATERIALS INC - BOARD HAS NOT CHANGED ITS RECOMMENDATION IN SUPPORT OF PENDING ALL-STOCK MERGER OF EQUALS WITH ENTEGRIS.VERSUM MATERIALS - BOARD AUTHORIZED MANAGEMENT AND ITS ADVISERS TO ENGAGE IN FURTHER DISCUSSIONS WITH, AND PROVIDE NON-PUBLIC INFORMATION TO, MERCK.  Full Article

Merck And GenScript To Cooperate To Accelerate Industrial Production Of Cell And Gene Therapies In China
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Merck KGaA ::MERCK AND GENSCRIPT INTEND TO COOPERATE TO ACCELERATE THE INDUSTRIAL PRODUCTION OF CELL AND GENE THERAPIES IN CHINA.SIGNING OF A NON-BINDING MEMORANDUM OF UNDERSTANDING.COLLABORATION TO BUILD GLOBAL-STANDARD PLATFORM FOR PLASMID AND VIRUS MANUFACTURING IN CHINA.MERCK PLANS TO PROVIDE COMPREHENSIVE PRODUCTS, SERVICES AND TRAINING TO GENSCRIPT ON MANUFACTURING.  Full Article

Merck Announces Collaboration With Iktos For Generative AI Technology
Thursday, 14 Mar 2019 

March 14 (Reuters) - MERCK KGAA ::ANNOUNCES COLLABORATION WITH IKTOS FOR GENERATIVE ARTIFICIAL INTELLIGENCE (AI) TECHNOLOGY.COLLABORATION AGREEMENT ENABLES MERCK KGAA, DARMSTADT, GERMANY, ACCESS TO IKTOS AI TECHNOLOGY ACROSS THREE DRUG DISCOVERY PROJECTS.  Full Article

BioXcel Therapeutics Announces Addition Of Merck KGaA, Darmstadt, Germany, And Pfizer To Clinical Collaboration With Nektar
Monday, 4 Mar 2019 

March 4 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES ADDITION OF MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER TO CLINICAL COLLABORATION WITH NEKTAR FOR DEVELOPMENT OF TRIPLE-COMBINATION THERAPY IN PANCREATIC CANCER.BIOXCEL THERAPEUTICS INC - BTI WILL BE RESPONSIBLE FOR INITIATING AND MANAGING CLINICAL PROGRAM.BIOXCEL THERAPEUTICS INC - MERCK KGAA, DARMSTADT, GERMANY AND PFIZER SUPPLYING AVELUMAB AND NEKTAR SUPPLYING NKTR-214..BIOXCEL THERAPEUTICS INC - BTI AND NEKTAR WILL EQUALLY SHARE ALL DEVELOPMENT COSTS.  Full Article

Merck KGaA: Our offer for Versum is clearly superior
Friday, 1 Mar 2019 

March 1 (Reuters) - Merck Kgaa ::SPOKESMAN SAYS WE REAFFIRM OUR VIEW THAT OUR PROPOSAL IS CLEARLY SUPERIOR, COMMENTING ON VERSUM STATEMENT.  Full Article

Entegris Comments On Merck KGaA’S Offer To Acquire Versum Materials
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Entegris Inc ::ENTEGRIS COMMENTS ON MERCK KGAA’S OFFER TO ACQUIRE VERSUM MATERIALS.ENTEGRIS INC - BELIEVE COMBINATION WITH VERSUM MATERIALS "IS HIGHLY COMPLEMENTARY AND STRATEGICALLY COMPELLING".  Full Article

Merck To Expand US Biopharmaceutical Research And Development Facility To Advance Innovative Clinical Pipeline
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - MERCK KGAA ::TO EXPAND US BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT FACILITY TO ADVANCE INNOVATIVE CLINICAL PIPELINE.EXPANSION OF RESEARCH AND DEVELOPMENT FOOTPRINT TO ACCELERATE SCIENCE AND INNOVATION IN ONCOLOGY, IMMUNO-ONCOLOGY AND IMMUNOLOGY GLOBALLY.MERCK KGAA, DARMSTADT, GERMANY INVESTING $70 MILLION IN U.S. RESEARCH & DEVELOPMENT HUB.  Full Article